Source comparison
Difference Between LL-37 and Thymosin Alpha-1: Research Comparison
Primary Mechanism Direct antimicrobial membrane disruption + chemotactic immune cell recruitment T-lymphocyte differentiation + dendritic cell maturation + cytokine modulation LL-37 acts locally and rapidly; Thymosin Alpha-1 modulates systemic adaptive immunit
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Direct antimicrobial membrane disruption + chemotactic immune cell recruitment
- T-lymphocyte differentiation + dendritic cell maturation + cytokine modulation
- LL-37 acts locally and rapidly; Thymosin Alpha-1 modulates systemic adaptive immunity over days
- Molecular Weight
- 4,493 Da (37 amino acids)
- 3,108 Da (28 amino acids)
- Structural differences dictate bioavailability and cellular uptake pathways
- Target Receptors
- FPRL1, P2X7, EGFR, IGFR, lipid membranes
- TLR2, TLR9, IL-2R, CD28 costimulatory pathway
- Non-overlapping receptor profiles explain distinct biological effects
- Onset of Action
- 15–60 minutes (antimicrobial), 6–12 hours (wound healing markers)
- 24–72 hours (T-cell markers), sustained effects 48–96 hours
- LL-37 suits acute infection models; Thymosin Alpha-1 fits chronic immunomodulation studies
- Typical Research Dosing
- 1–50 µg/mL in vitro; 1–10 mg/kg subcutaneous in vivo
- 0.1–0.5 mg/kg twice weekly (animal); 1.6 mg twice weekly (human trials)
- Dosing schedules reflect pharmacokinetic and mechanistic differences
- Serum Half-Life
- 2–4 hours (proteolytic degradation by elastase)
- 30–120 minutes (receptor-mediated clearance)
- Both require repeat dosing; effects persist longer for Thymosin Alpha-1 due to transcriptional cascades
- Antimicrobial Efficacy
- Direct bactericidal (MIC 2–16 µg/mL), fungicidal, antiviral (enveloped)
- None. Immune enhancement indirectly supports pathogen clearance
- LL-37 is the frontline antimicrobial; Thymosin Alpha-1 augments adaptive immunity
- Wound Healing Role
- Promotes angiogenesis, keratinocyte migration, collagen deposition via EGFR/VEGFR2
- Minimal direct wound healing; influences repair indirectly via cytokine milieu
- LL-37 accelerates acute wound closure; Thymosin Alpha-1 may benefit chronic inflammatory wounds
- Post-Reconstitution Stability
- 14 days at 2–8°C
- 21–28 days at 2–8°C
- Thymosin Alpha-1 offers slightly longer working window after mixing